- Current report filing (8-K)
February 07 2011 - 2:40PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
February 3, 2011
|
Gilead Sciences, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
0-19731
|
94-3047598
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
333 Lakeside Drive, Foster City, California
|
|
94404
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
650-574-3000
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 1 REGISTRANTS BUSINESS AND OPERATIONS
Item 1.01 Entry into a Material Definitive Agreement.
On February 3, 2011, Gilead Sciences Limited (GSL), a wholly-owned subsidiary of Gilead Sciences,
Inc. (Gilead), and PharmaChem Technologies (Grand Bahama) Ltd. (PharmaChem) entered into an
addendum (Addendum) to the Tenofovir Disoproxil Fumarate Manufacturing Supply Agreement dated as of
July 17, 2003, as previously amended (Supply Agreement).
Under the Supply Agreement, PharmaChem manufactures and supplies GSL and third parties authorized
by GSL with commercial supply of bulk tenofovir disoproxil fumarate, the active pharmaceutical
ingredient of Viread
®
and one of the active pharmaceutical ingredients of
Truvada
®
and Atripla
®
. The Addendum, among other things, extends the term of
the Supply Agreement from December 31, 2012 to December 31, 2016, provides GSL an option to further
extend the term to December 31, 2017, and sets forth GSLs minimum total purchase obligations and
corresponding pricing projections for the extension period.
The foregoing description of the Addendum contained in this Item 1.01 does not purport to be
complete and is qualified in its entirety by reference to the complete text of the Addendum, which
will be filed, with confidential terms redacted, with the Securities and Exchange Commission as an
exhibit to the registrants Quarterly Report on Form 10-Q for the period ending on March 31, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Gilead Sciences, Inc.
|
|
|
|
|
|
February 7, 2011
|
|
By:
|
|
/s/ Robin L. Washington
|
|
|
|
|
|
|
|
|
|
Name: Robin L. Washington
|
|
|
|
|
Title: Senior Vice President and Chief Financial Officer
|
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024